In another study, Intellia Therapeutics again developed NTLA‐2001 gene therapy, which is a CRISPR/Cas9 system to knock out the transthyretin (TTR) gene in patients with the progressive, fatal disease hereditary transthyretin amyloidosis, which is caused by mutation of the TTR gene. This evidence concerns the gene TTR and amyloidosis.